Delivery Order SPE2DR25D6029-SPE2DR26FXP6M
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $6,844.76 to AmerisourceBergen Drug Corp for AZSTARYS CAPS 39.2MG/7.8MG on September 23, 2025, with completion expected by September 24, 2025. This competitively awarded, firm fixed-price contract requires no set-aside designation and represents a pharmaceutical supply delivery to support federal medical procurement requirements. The award was placed of performance at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $3,856.69 to AmerisourceBergen Drug Corp for AZSTARYS CAPS 39.2MG/7.8MG on August 20, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency Medical Supply Chain awarded a $6,044 delivery order to AmerisourceBergen Drug Corp for AZSTARYS CAPS 39.2MG/7.8MG on October 16, 2025, with an ultimate completion date of October 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a continuation of the critical pharmaceutical supply relationship between the federal government and AmerisourceBergen, one of the nation's largest pharmaceutical distributors. The...
- The Defense Logistics Agency awarded a $14,687.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Imdelltra 10 mg vials, with a completion date of June 9, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $34,138.30 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025. This non-set-aside competitive award serves as a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $57,029.60 by the Defense Logistics Agency's Medical Supply Chain. The contract, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $50,750.68 by the Defense Logistics Agency's Medical Supply Chain. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 28, 2025, and carries no set-aside designation. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $39,461.76 by the Defense Logistics Agency's Medical Supply Chain on September 15, 2025, with an ultimate completion date of September 16, 2025. This non-set-aside competitive award (Contract Number 4569447204) represents a child order under a larger indefinite delivery contract vehicle. The delivery order is scheduled for performance at the vendor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 21, 2025. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $10,330.72 by the Defense Logistics Agency's Medical Supply Chain for pharmaceutical and medical supply products. The award, issued on September 22, 2025, with an ultimate completion date of September 23, 2025, is structured as a firm fixed-price delivery order under a competitive, non-set-aside procurement. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D6029Indefinite Delivery Contract
- SPE2DR25D6029-SPE2DR26FXP6MDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $70,012.80 to AmerisourceBergen Drug Corp for the supply of STRENSIQ 80 mg/0.8 mL vials. The contract is structured as a firm fixed price delivery order with an ultimate completion date of November 13, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. STRENSIQ is a specialized pharmaceutical product for the treatment of alkaline phosphatase deficiency, reflecting the critical nature of the Defense Logistics Agency's medical supply procurement. The delivery order demonstrates AmerisourceBergen's ongoing role as a key federal pharmaceutical distributor serving the Defense Health Agency and other military healthcare systems. As a child contract under the larger SPE2DX prime IDC, this award exemplifies the company's capability to fulfill specialized medical commodity requirements through the DLA's structured contracting approach for supporting military medical readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.0k | 10/22/25 |